EYPT EyePoint, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biopharma developing sustained intraocular drug delivery therapeutics for serious retinal diseases leveraging proprietary bioerodible Durasert E™ technology
• • New emphasized product: DURAVYU™, a novel multi-mechanism VEGF receptor, PDGF, and IL-6/JAK1 inhibitor in Phase 3 trials for wet AMD and DME, first patient dosed in DME Phase 3 in Feb 2026
• • Strategic shift: Transition from early to pivotal late-stage global Phase 3 trials with enrollment completion in two wet AMD studies (LUGANO, LUCIA) and initiation of two DME studies (COMO, CAPRI)
• • Quantitative metric: Over 900 patients enrolled across two Phase 3 wet AMD trials, additional ~480 patients planned for Phase 3 DME trials; Phase 2 VERONA trial showed +10.3 letters BCVA improvement in subgroup vs +3.0 aflibercept
• • Noteworthy fact: DURAVYU's intracellular multi-MOA acting on VEGF receptors plus anti-inflammatory IL-6 signaling constitutes a new treatment paradigm with potential 6-month sustained delivery reducing treatment burden by over 85%

Risk Factors

• • DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026
• • Clinical trial delay risk: DURAVYU Phase 3 topline data expected in 2026, cash runway extends only into Q4 2027
• • Manufacturing risk: inability to scale DURAVYU production could delay Phase 3 trials and commercialization
• • Competitive risk: approval and market acceptance of DURAVYU may be impacted by alternative wet AMD treatments and generics
• • Liquidity risk: $306.1M cash runway likely sufficient only through Q4 2027, requiring uncertain future capital raises that may dilute shareholders

Management Discussion & Analysis

• • Revenue $31.4M down 28% YoY from $43.3M; product sales fell 50% to $1.6M, license/collab revenues down 57% to $16.7M, royalty income up 708% to $13.0M
• • Operating expenses $274.8M up 45% YoY from $189.1M; R&D $221.0M up 66%, G&A $51.6M down 1%; operating loss $243.4M vs $145.9M, loss margin ~776% vs 337% (loss/net loss ÷ revenue)
• • Best segment: Royalty income $13.0M (+708%); Worst: License/collab revenue down $21.8M to $16.7M
• • Financing: Raised $172.5M via public offering + $11.6M ATM sales; cash and securities $306.1M at year-end; Operating cash outflow $240.1M; no buybacks or dividends disclosed
• • Outlook: Phase 3 DURAVYU trials enrollment complete, data expected mid-2026; first DME patient dosed Feb 2026; settled DOJ investigation in principle with ~$4.7M payment; cash runway into Q4 2027

What are the latest EYPT SEC filings in 2026?

EyePoint, Inc. (EYPT) has filed a 10-K annual report on March 5, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did EYPT file its most recent 10-K annual report?

EyePoint, Inc. (EYPT) filed its most recent 10-K annual report on March 5, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view EYPT 10-Q quarterly reports?

EyePoint, Inc. (EYPT)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every EYPT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has EYPT filed recently?

EyePoint, Inc. (EYPT)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find EYPT insider trading activity (Form 4)?

SignalX aggregates every EYPT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does EYPT file with the SEC?

EyePoint, Inc. (EYPT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new EYPT filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for EyePoint, Inc. (EYPT).

What is EYPT's SEC CIK number?

EyePoint, Inc. (EYPT)'s SEC CIK (Central Index Key) number is 1314102. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1314102 to look up all EYPT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find EYPT return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from EyePoint, Inc. (EYPT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.